Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really? So fda said we want these endpoints and mf said nope we are good with the old ones? That doesn’t sound much like a back and forth to agree on endpoints. That is the fda saying we will accept these endpoints and mf, in all his brilliance, saying no I feel like screwing everyone and wasting the past year so I will stick with the old ones. I’m sure you will have an excuse for that as well. Just make sure you buy all the shares in the next dilution to fund the rest of the trial that has no patients. It takes some sort of idiot not to unblind a trial that you know you can’t finish. At this point he is just dragging this thing out. Unblind and sell based on the pcr data and maybe they can salvage a couple hundred mill.
Yes and the PR is a written response to the public regarding said written responses from the GDA where RVVTF said no thanks we will ignore and continue with previous end points which were already rejected by the FDA.
Hospitalizations and deaths are no longer a thing to 99%+ of the public with these weaker strains. Hence why FDA wants time to resolved symptoms.
Does this drug help people who get sick with covid get better faster yes or no? That’s it. Thats what the FDA wants to know. Not whether they will die.
The FDA is looking for essentially a stronger Dayquil for covid. Plain and simple.
Revive is ignoring that request apparently. Or the data doesn’t support it. That simple
As recently reported by the Company, the FDA has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The goal date for the FDA to provide its written responses is March 7, 2023.
TYPE C Meeting..............When requesting a Type C meeting, Sponsors can request a written response to their questions rather than an in-person meeting, videoconference, or teleconference. A sponsor may request a face-to-face meeting, but the FDA may decide that only a written response is necessary.
Yes, written correspondence would equate to a "back and forth" between parties.
Some should learn to Read and Comprehend before posting laughably mindless comments. lololsss
LOL 20 cents?! This hasn’t seen 20 cents in six months. Now its going to .20 on this news?! Pump pump pump
The last boy scout is buying them all
It ain't over till the fat lady sings. The US Banks crashed and burned and this week rose from the dead like the Phoenix rising.
RVVTF is up 66% in 2 two days on heavy volume since the opening crash monday, market sell (likely MM shorts tripping fools stop loss orders) And the shares I bought the knife on a day ago are up 20% today.
This beast could be back at 20 cents in week.
Did you sell all your shares or have you held on to all / some, Trip?
I wouldnt mind grabbing some more,just dont have any cash left right now.
Lotto ticket buys
People here are buying. Maybe a lot now?
Sorting out the noise could be helping folks call their shots better.
Who is buying all these shares.
Half a million plus shares bought over the last hour or so. Nobody would buy at a nickel for no good reason. Gotta have hope!
MF raised 4.3mil at .15 valuation
He’s got cash how he will spend it is anyone’s guess
Most importantly, glad to see you're still around Gatorca. And congratulations on the cheapies.
Where there truly is BIG money to be made, there should surely be a big player wanting to make that money. My hope, is that deals are already being made between MF and whoever that may be and we all get to put RVVTF behind us with some profit to show for sticking around.
Many lessons learned these last three years. I'd like to put them in to practice.
I bought many in the .03 range well for me :) Rubber yesterday acutally average down .01 lol still over %50 down since under .10.
ps. yea im still alive, yesterday talked to ,Bluehorseshoe, Rio and even Ecomike
pps. Cw almost sure rio is still holding but even bored of the tweets.
ppps. my main worry like others im sure is can Mf get a partner with the 210 data.... otherwise how is he getting more money so this trial does not go another year to finish....to fund. and it is good to see this in the news...to develop a defined recruitment plan that prioritizes subjects recognized to be at higher risk for developing severe COVID-19 to achieve the Study’s objectives.
But without partner how is this not going to take until end of this year or so?
Ps.Im holding until whatever happens to much DD how good Bucillamine should work from Bmt,Ecomike ,Ninetendo64
pppps. glad I have couple days off damn this northern lights vape is very relaxing :)
I added some. I haven’t sold yet
I wish I had been able to buy in the .03's and sold today in the high .04's. Who wouldn't?
And there you have it. So called experts pumping at .15 still buying in the .03s
Don’t worry ric said he was buying all shares under a nickel
Yes a huge thanks for the huge donation (3s) today.......expecting an easy 3 - 5+ bagger in the coming weeks/month(s) from these levels.
Like I had mentioned several times before, ive essentially traded the same stock from the 08 crisis to this day so ignoring all the noise wasnt very difficult.
Learned a very valuable lesson from the last fin crisis and its aftermath about holding out for the ""BIG SCORE"" and have never looked back since.....once bitten, 1000X shy!!!
Has been interesting to watch all the various levels of ""meltdown"" over this mornings Pr....... of course the faux analysis from halfwits were entertaining as expected. lololsss
The only thing thats changed a bit is that my view towards rvv management, which includes the med team, is that I now believe they are inept.......as far as buccy goes, im sticking with the solid science.
@joebenson........wheres hotmeat???
A tad bit slow innit.............................
Hey Blue. I was wondering when you would chime in today. Gator and Gio, as stated by Rubber, are like me. They are stewing about the pps, the delays of unblinding the data and several dozen other things I can think of but don't care to list. It just a long term hold for me,but very likely about 7 more years at work than I intended. Unless a miracle appears from some big Pharm savior, all the other stuff is just too far away to get excited.
ps. Rio- If you read this, your posts were always informative. I'm curious if you moved on- I can't blame you.
pps. Here is my new blackjack analogy. We have a 16 and the dealer has an Ace. Maybe a long term covid possibility, but I can't even think right now. I keep telling myself it's just a paper loss. Ugh.
Ecomike…it’s over. You’re smart man.
Can I join the Ecomike bowling team as im not going anywhere,just holding.
EcoMike, I have 16 pound diamond balls and a 300 to my name.. these things take time and endured pressure to make......diamonds, 300's, and .......
As a ditch digger once told, we wait...
You bought his shares.
Got that right brother
Eco
I'm a bowler. Only use a 15.lb ball these days because of technology and expect the same from the RVVTF CEO!
I'm not blowing smoke up someone's proverbial and I sure am not in league with anyone, but I've watched naysayers dispute Ecomike's positive claims on a stock that seemed dead, and low and behold, if I'd had money to invest in that stock I would have enjoyed hefty gains.
For a newbie who has nothing left right now but hope in what seems like a shitty situation I'll trust the words of someone with a track record of being right when everyone else was wrong.
P. S. I hope Giovanni and Gatorca didn't top themselves today.
LOL now you pivot to the orphan drug status and shrooms? You have no shame.
Let me guess you saw this all coming?
Yes, and that was our hope with RLFTF too. But the big pharma buyout never happened. It's just a pipe dream IMO. But then again, stranger things have happened. There are investors on RLFTF that lost hundreds of thousands of dollars. And I'm sure that there are some here are sitting on those type of losses too. However, the insiders always win, and Michael Frank still gets his big fat salaries and bonuses. It is what it is.
LMAO, today's reading comprehension panic disabled, $RVVTF selling market took itself to the cleaners in a panic selloff today being led to the culling by fake news interpretations of the earlier US PR this morning.
Later today this came out:
https://newsytrends.com/2023/03/20/revive-therapeutics-ltd-cse-rvv-otcmkts-rvvtf-reverses-off-52-week-lows-as-fda-adjusts-endpoints-in-bucillamine-trials-more-on-rvv-psilocybin-clinical-study/
Revive Therapeutics Ltd (OTCMKTS: RVVTF) is a biotech sleeper that hit new 52 week lows on Monday after the FDA adjusted the endpoints of its Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19. The Company is still committed to advancing the clinical and commercial development of Bucillamine and decided that in the best interest of the Study to preserve and not compromise the integrity of the Study and keep the blinded data intact to support a potential FDA approval in the future. Revive has a lot going on besides this; the Company was granted orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis by the FDA and has entered into a clinical trial agreement with The Trustees of Indiana University to develop and manage a clinical study entitled, “Use of Cannabidiol as an adjunct therapy for difficult to treat autoimmune hepatitis.”
Revive Therapeutics made a legendary run up the charts during 2020 culminating in a run to over $0.70 per share in the US. Now the stock has reversed off $0.0296 lows in the US after over reacting on the Bucillamine update.
Revive has a lot going on; the Company is evaluating psilocybin in a Phase 1/2 clinical study for methamphetamine use disorder via a research collaboration with the University of Wisconsin-Madison, developing a novel psilocybin oral thin film strip through a feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films as well as developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform under its research collaboration with North Carolina State University. We will be updating on Revive Therapeutics when more details emerge ...
Revice hit new lows on Monday after the Company announced an update from the FDA Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19. On March 8th, 2023, the Company received the Type C meeting written responses from the FDA to obtain agreement on the proposed protocol endpoints for the Company’s Study. The FDA recommended that the Company’s proposed primary symptom-based endpoint should cover the evaluation of time to sustained recovery assessed over an appropriate duration, evidence of subjects experiencing resolution of COVID-19 related symptoms and the element of sustained symptom resolution.
After a further in-depth review and analysis of the FDA recommendations with members of the Company’s clinical trial team, including its statistician, regulatory affairs, medical affairs, and clinical research advisors, the Company has decided that in the best interest of the Study to preserve and not compromise the integrity of the Study and keep the blinded data intact to support a potential FDA approval in the future. As a result, the Company is committed to advancing the clinical and commercial development of Bucillamine and plans to pursue the following activities:
Continue discussions with the FDA on a pathway for future potential regulatory approval under the current Study’s objectives, which the FDA and DSMB continue to support;
Work with the Study’s current participating clinical sites and potential new clinical sites to develop a defined recruitment plan that prioritizes subjects recognized to be at higher risk for developing severe COVID-19 to achieve the Study’s objectives;
Determine potential opportunities of unblinding additional data related to the Study for evaluation to support future discussions with the FDA, and further studies for Long COVID or COVID symptom-related conditions, which the FDA provided advice to pursue, and various infectious and respiratory disorders;
Develop reformulation strategies of Bucillamine to expand on its potential therapeutic utility targeting rare disorders that may come with regulatory incentives awarded by the FDA, such as orphan drug (i.e. ischemia-reperfusion injury, cystinuria), fast track, and breakthrough therapy designations; and
Secure alliances with strategic partners, including pharmaceutical companies, to achieve Bucillamine’s full commercial potential.
"Currently trading at a $22 million market valuation Revive Therapeutics os is 320,008,751 with 315,580,417 shares in the public float. "
Bullish head and shoulders 3 year pattern is a buy. And there is 100% rally gap over head to cover from the morning low.
Ironically, I think big pharma is the only hope. If they partner/purchase buc it would most likely get fast-tracked. They managed to get their stuff approved in almost a rubber stamp manner.
That's been my key learning with all this. The little guy doesnt have much of a chance.
I can think of something that is more unethical and immoral. I'm sure i don't need to tell YOU, and i'm sure your many followers know what that is.
Interesting that hedge fund backed, BP backed shorts are so motivated to push a fake news scam and fraud narrative about $RVVTF and the CEO while the US FDA, US Justice Department, FBI and SEC have made no such claims.
Pushing a fake news scammy narrative to profit off of folks that invested to save lives is unethical and immoral.
And just like RLFTF, the CEO (Michael Frank) and other fat cat insiders still get their fat salaries and bonus checks. No loss for them. They still did just fine in the pandemic.
As predicted, RVVTF followed the same path as RLFTF. Both foreign tiny biotechs, and the FDA doesn't give them the attention they give USA Big Pharma. I saw this coming, and I feel bad for the longs. I've also never had any faith in this CEO's competency level. He's always been too hooked on shrooms. At least the O/S is not in the stratosphere like it is with RLFTF, so I don't think an R/S is on the horizon just yet. But clearly investor patience has worn thin, COVID is winding down, and the big money has already been made for most with this pandemic. JMHO.
This sucks bad. We all got taken to the woodshed by this CEO three years. Now is going to be 3 years for this to even go above a dime. I had hope with this stock. When I saw ECO pumping the stock. I know it's was all over. God luck CW.
A lot of lawsuit talk on the reddit board. Even Biomedical Trader blamed management this morning as to the reason for this disaster.
If you are right about us being scammed, CEO Michael Frank should go into hiding. Seriously.
I fear the sentiment is as it is over on the Reddit board and MF will drag this out as long as possible to collect his six figure salary.
As was stated over there we were told they would unblind the data regardless whether or not the FDA approved the end points. Now he claims they will not unblind the data.
This has all the markings of a scam at this point. Unfortunately I’ve been a part of these before on the OTC with fraudulent CEO’s milking it to the last drop
Good luck on your increased investment. If I had powder to bet with I believe one half of my brain would have talked me in to buying more on the dip because of A.
As it is I continue to hold and hope that A will be the reason that an entity with way more clout is already planning its move to take Bucillamine to the finish line.
Me too. Broke it down to 2 bets.
A. on the science, with good promise and
B. on the company, a long shot.
I bought today, but not because of B.
A part of me wishes it was well and truly over, even with the massive loss entailed. At least then one could move on with a tried but failed mindset instead of more holding and hoping. Selling would equally suck because of FOMO.
Fress sure did make a smart move back in December '20.
Your not alone CW,all us longs are feeling the pain.Lets hope we can get some back.
Followers
|
339
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36630
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |